Ascendis Pharma

Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Ascendis reported phase 3 growth disorder data that exceeded analyst expectations and positions the biotech to file for approval next year.

Nick Paul Taylor Sep 17, 2024 9:36am

very busy graphic of scientists working on an eye with one standing on a ladder preparing drops another set to apply a cont

Eyconis launches with $150M and Ascendis' eye disease meds

Jan 29, 2024 11:03am

Photo of two hands shaking

Ascendis sells Japan rights to Skytrofa, 2 other drugs for $70M

Nov 29, 2023 8:25am

Stop sign

FDA unexpectedly halts Ascendis' drug review

Apr 3, 2023 10:22am

topic report

Illustration connected puzzle pieces with the acronym MA

10 top M&A targets in biotech for 2023

Jan 30, 2023 3:00am

Clinical trial microscope

Ascendis scores in phase 3 trial, a boost to endocrine portfolio

Mar 14, 2022 11:15am